Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth
Syndax Pharmaceuticals (SNDX) posted strong Q3 results, driven by robust Revuforj and Niktimvo sales, despite a slight revenue miss. SNDX's commercial ramp is accelerating, with Revuforj prescriptions up 25% and management confident cash reserves will fund operations to profitability. 2026 revenue projections for SNDX range from $245M to $512M, depending on growth scenarios, but risks include reimbursement and competitive shifts.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript
Syndax Pharmaceuticals, Inc. ( SNDX ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Okay. Well, thanks for joining.
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its addressable market, reinforcing first-mover advantage and supporting $1B+ peak sales potential. Niktimvo's robust uptake and Incyte partnership will aid the march to profitability, while also providing significant downside cushion.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.7 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to a loss of $0.98 per share a year ago.
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. ( SNDX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Keith Goldan - CFO, Treasurer & Chief Accounting Officer Conference Call Participants Priyanka Grover - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Ellen Horste - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Justin Zelin - BTIG, LLC, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Jason Zemansky - BofA Securities, Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Third Quarter 2025 Earnings Conference Call.
Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Ellen Horste - TD Cowen, Research Division Justin Zelin - BTIG, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Conference Call to Discuss the FDA approval of Revuforj in Relapsed/Refractory NPM1 Mutated AML.
Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome, everyone, to the, I believe, the last session of the first day of Citi's Biopharma Back-to-School Summit. I'm Yigal Nochomovitz, biotech analyst here at Citi.
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Syndax Pharmaceuticals: A Tale Of Two Drug Launches
Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo launch in chronic GVHD. Incyte is the ideal partner for GVHD, being highly familiar with this space and the 50/50 split in the US provides a significant downside cushion to investors.
Syndax Pharmaceuticals: The Story Brightens
Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are driving rapid revenue growth, with management now targeting $10 billion in peak sales for both drugs combined. Analysts remain bullish and profitability could arrive by FY 2028, a year earlier than consensus estimates before Q2 numbers came out.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Metzger - CEO & Director Nicholas Botwood - Head of Research and Development and Chief Medical Officer Sharon Klahre Peter Richard Lawson - Vice President of Investor Relations & Communications Steven Closter - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Dingding Shi - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Kevin Strang - Goldman Sachs, Research Division Mayank Mamtani - B.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.8 per share a year ago.
